Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 in ES-SCLC (Phase II, single-arm, China)
CTR20233061Phase 2Terminated
- Sponsor
- Hansoh Pharmaceutical Group
- Start
- Sep 2023
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan in small cell lung cancer (SCLC), sponsored by Hansoh Pharmaceutical Group. Started Sep 2023; status: terminated.
02
Drugs
risvutatug rezetecan
03
Conditions
small cell lung cancer (SCLC)
Beyond the preview
Go deeper on CTR20233061.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20233061.